Description: Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Home Page: www.psyencebiomed.com
121 Richmond Street West
Toronto,
ON
M5H2K1
Canada
Phone:
416-346-7764
Officers
| Name | Title |
|---|---|
| Mr. Jody Aufrichtig | Co-Founder, Executive Chairman & Strategic Business Development Officer |
| Dr. Neil Maresky M.D. | CEO & Director |
| Mr. Warwick Ron Corden-Lloyd | Chief Financial Officer |
| Ms. Taryn Vos | General Counsel |
| Ms. Mary-Elizabeth Gifford | Chief of Global Impact |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2024-01-25 |
| Fiscal Year End: | March |
| Full Time Employees: | 0 |